Factors associated with coverage of praziquantel for schistosomiasis control in the community-direct intervention (CDI) approach in Mali (West Africa)

Infectious Diseases of Poverty

Ogobara Doumbo¹  Oumar Sankaré²  Bourema Kouriba¹  Boubacar Bary¹  Abdoulaye Dabo¹ 

[1] Department of Epidemiology of Infectious Diseases, Faculty of Medicine, Pharmacy and Dentistry, UMI 3189, University of Sciences, Techniques and Technologies of Bamako, Box 1805, Bamako, Mali;High Institute for Training and Applied Research, Box 475E, Bamako, Mali

关键词: Mali;    Diéma;    Coverage rate;    Community-directed intervention;    Praziquantel;    Schistosomiasis;   

Others  :  805297
DOI  :  10.1186/2049-9957-2-11

 received in 2013-02-20, accepted in 2013-05-13,  发布年份 2013

【 摘 要 】

Background

Despite the progress made in the control of Neglected Tropical Diseases (NTD), schistosome and soil-transmitted helminth infections are far from being effectively managed in many parts of the world. Chemotherapy, the key element of all control strategies, is faced with some difficulties in terms of access to treatment. Our study aims to describe the factors involved in the success or failure of the community-directed intervention (CDI) approach through control programmes, which aims to achieve consistent high coverage at affordable and sustainable costs in endemic areas.

Methods

The CDI approach was carried out from December 2007 to October 2008 in ten villages of the district of Diéma, Mali. At inclusion, each child part of the study’s sample was interviewed and submitted for a physical examination. The study focused on: data collection, treatment of the eligible population, evaluation of the treatment coverage, performance of community drug distributors (CDDs), and the involvement and perception of populations.

Results

A total of 8,022 eligible people were studied with a mean coverage rate of 76.7%. Using multiple regression, it was determined that receiving praziquantel as treatment was associated with five factors: belonging to the Fulani or Moorish ethnic minority versus the Bambara/Soninke, use of the central versus the house-to-house drug distribution mode, the ratio of the population to the number of CDDs, the lack of supervision and belonging to the age group of 15 years or above (p<0.05). As well as that, it was found that the presence of parallel community-based programmes (HIV, tuberculosis) that provide financial incentives for community members discouraged many CDDs (who in most cases are volunteers) to participate in the CDI approach due to a lack of incentives.

Conclusions

The findings indicate that the success of the CDI approach depends on, amongst other things, the personal characteristics of the respondents, as well as on community factors.

【 授权许可】

   
2013 Dabo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J: Schistosomiasis and water resources development: systematic reviews, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006, 6:411-425.
• [2]Hotez P: Mass drug administration and integrated control for the world’s high-prevalence neglected tropical diseases. Clin Pharmacol Ther 2009, 85:59-661.
• [3]Van der Werf MJ, De Vlas SJ, Brooker S, et al.: Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003, 86:125-139.
• [4]Brinkmann UK, Werler C, Traore M, Korte R: Experiences with mass chemotherapy in the control of schistosomiasis in Mali. Trop Med Parasitol 1988, 39:167-174.
• [5]Traoré M, Maude GH, Bradley DJ: Schistosomiasis haematobia in Mali: prevalence rate in school-age children as index of endemicity in the community. Trop Med Int Health 1998, 3(3):214-221.
• [6]Clements AC, Bosqué-Oliva E, Sacko M, Landouré A, Dembélé R, Traoré M, Coulibaly G, Gabrielli AF, Fenwick A, Brooker S: A comparative study of the spatial distribution of schistosomiasis in Mali in 1984–1989 and 2004–2006. PLoS Negl Trop Dis 2009, 3(5):e431.
• [7]World Health Organization Expert Committee: Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organization Technical Reports Series 2002, 912:1-57.
• [8]CDI Study Group: Community-directed interventions for priority health problems in Africa: results of a multicounty study. Bull World Health Organ 2010, 88(7):509-518.
• [9]Mutalemwa P, Kisinza WN, Kisoka WJ, Kilima S, Njau J, Tenu F, Nkya T, Magesa SM: Community directed approach beyond ivermectin in Tanzania: a promising mechanism for the delivery of complex health interventions. Tanzanian Journal of Health Research 2009, 11:116-125.
• [10]Massa K, Magnussen P, Sheshe A, Ntakamulenga R, Ndawi B, Olsen A: The effect of the community-directed treatment approach versus the school-based treatment approach on the prevalence and intensity of schistosomiasis and soil-transmitted helminthiasis among schoolchildren in Tanzania. Trans R Soc Trop Med Hyg 2009, 103(1):31-37.
• [11]Seketeli A, Adeoye G, Eyamba A, Nnoruka E, Drameh P, Amazigo UV, Noma M, Agboton F, Aholou Y, Kale OO, et al.: The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 2002, 96(Suppl 1):S15-S28.
• [12]Sama MTH, Ngang P, Liese BH, Amazigo U, Seketeli A: A multi-centre study of community-directed ivermectin distributors’ (CDDs’) involvement in other healthcare and development programme activities in Cameroon, Togo, Sudan. Nigeria and Uganda. Tropical Doctor 2003, 33(4):237-241.
• [13]Anto F, Asoala V, Anyorigiya T, Oduro A, Adjuik M, Akweongo P, Aborigo R, Bimi L, Amankwa J, Hodgson A: Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. Trop Med Int Health 2011, 16(9):1112-1119.
• [14]Njenga SM, Wamae CN, Njomo DW, Mwandawiro CS, Molyneux DH: Impact of tworounds of mass treatment with diethylcarbamazine plus albendazole in Malindi, Kenya. Trans R Soc Trop Med Hyg 2008, 102(10):1017-1024.
• [15]Campagne G, Garba A, Bakire H, Vera C, Sidiki A, Chippaux JP: Continued ultrasonic follow-up of children infected with Schistosoma haematobium after treatment with praziquantel. Trop Med Int Health 2001, 6:24-30.
• [16]Werler C: Annual report of Schistosomiasis and Soil-transmitted Helminths National Control Programme (PNLSH). Bamako; 2007:38.
• [17]World Health organization: Preventive chemotherapy in human helminthiasis. A manual for health professionals and programme managers. Geneva: World Health Organization Report; 2006:74.
• [18]Katabarwa NM, Mutabazi D, Richards FOJR: Controlling onchocerciasis, ivermectin-treatment programmes in Uganda: why do some communities succeed and others fail? Ann Trop Med Parasitol 2000, 94:343-352.
• [19]Dembélé R: Strategic plan for fighting against neglected tropical diseases (NTD) 2007–2011. Bamako; 2007–2011. [Integration of mass chemotherapy strategy for trachoma, lymphatic filariasis, onchocerciasis, schistosomiasis and soil-transmitted helminths control. Report of Schistosomiasis and Soil-transmitted Helminths National Control Programme (PNLSH)]
• [20]UNDP/World bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR): Community-Directed Treatment with Ivermectin. Geneva: World Health Organization; 1996.
• [21]African Programme for Onchocerciasis Control: Community-Directed Treatment with Ivermectin (CDTI). Ouagadougou: A Practical Guide for trainers of Community-Directed Distributors. APOC; 1998.
• [22]UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR: Community-Directed Treatment of Lymphatic Filariasis in Africa. Geneva; 2000. TDR/IDE/RP/CDTI/00.2
• [23]World Health Organization: Report of a multi-centre study in Ghana and Kenya. Geneva: World Health Organization; 2000.
• [24]Boussinesq M, Chippaux JP, Ernould JC, Quillevere D, Prod’hom J: Effect of repeated treatments with ivermectin on the incidence of onchocerciasis in northern Cameroon. AmJTrop Med Hyg 1995, 53:63-67.